We came across a bullish thesis on Sana Biotechnology, Inc. (SANA) on wallstreetbets Subreddit Page by Intrepid_Web5454. In ...

The pancreatic cell therapy is engineered with Sana’s (NASDAQ:SANA) hypoimmune, or HIP, technology. Sana (SANA) said results showed the survival and function of pancreatic beta cells at four ...

Sana’s HIP technology is designed to overcome the immunologic rejection of allogeneic cells. In type 1 diabetes, it also evades the autoimmune rejection of pancreatic beta cells. UP421 cells ...

First-in-Human Study Provides Evidence that Sana’s Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression Results ...

Sana’s HIP technology is designed to overcome immunologic rejection of allogeneic cells, and in type 1 diabetes, also to evade the autoimmune rejection of pancreatic beta cells. UP421 cells were ...

Will companies approach Sana for permission to license its technology, and would Sana be amenable to such an arrangement? That in itself could be a multi-billion dollar revenue / royalty ...

Shares of Sana Biotechnology surged after the company ... an allogeneic primary islet cell therapy engineered with its hypoimmune technology, into a patient with type 1 diabetes without the ...

an allogeneic primary islet cell therapy engineered with Sana’s hypoimmune (HIP) technology, into a patient with type 1 diabetes without the use of any immunosuppression. The study was conducted ...